You have no items in your shopping cart.
- Item 1 of 2
Human FGF R3 [orb2994172]Unconjugated
SDS-PAGE: Greater than 95% as determined by reducing SDS-PAGE.
Predicted: 39 KDa. Observed: 60-75 KDa, reducing conditions
1 mg, 500 μg, 50 μg, 10 μg- Human FGF R3 [orb2994760]
Unconjugated
SDS-PAGE: Greater than 95% as determined by reducing SDS-PAGE.
Predicted: 64.8 KDa. Observed: 95-110 KDa, reducing conditions
1 mg, 500 μg, 50 μg, 10 μg - Human FGFRL1 [orb2995021]
Unconjugated
SDS-PAGE: Greater than 95% as determined by reducing SDS-PAGE.
Predicted: 39.9 KDa. Observed: 65 KDa, reducing conditions
1 mg, 500 μg, 50 μg, 10 μg - Human FGFR2 beta [orb2993025]
Unconjugated
SDS-PAGE: Greater than 95% as determined by reducing SDS-PAGE.
Predicted: 52.2 KDa. Observed: 72-95 KDa, reducing conditions
1 mg, 500 μg, 50 μg, 10 μg - Human FGFR2IIIb [orb2993041]
Unconjugated
SDS-PAGE: Greater than 95% as determined by reducing SDS-PAGE.
Predicted: 66.5 KDa. Observed: 85-120 KDa, reducing conditions
1 mg, 500 μg, 50 μg, 10 μg - Human FGFR2IIIb [orb2993042]
Unconjugated
SDS-PAGE: Greater than 95% as determined by reducing SDS-PAGE.. SEC-HPLC: Greater than 95% as determined by SEC-HPLC.(QC verified)
Predicted: 26.2 KDa. Observed: 40-70 KDa, reducing conditions
1 mg, 500 μg, 50 μg, 10 μg - Human FGFR2IIIc [orb2993043]
Unconjugated
SDS-PAGE: Greater than 95% as determined by reducing SDS-PAGE.. SEC-HPLC: Greater than 95% as determined by SEC-HPLC. (QC verified)
Predicted: 66.5 KDa. Observed: 85-120 KDa, reducing conditions
1 mg, 500 μg, 50 μg, 10 μg - Human FGFR2IIIb [orb2993044]
Unconjugated
SDS-PAGE: Greater than 95% as determined by reducing SDS-PAGE.. SEC-HPLC: Greater than 95% as determined by SEC-HPLC. (QC verified)
Predicted: 52.3 KDa. Observed: 70-90 KDa, reducing conditions
1 mg, 500 μg, 50 μg, 10 μg - Human FIBP [orb2993373]
Unconjugated
SDS-PAGE: Greater than 95% as determined by reducing SDS-PAGE.
Predicted: 41.8 KDa. Observed: 40-50 KDa, reducing conditions
1 mg, 500 μg, 50 μg, 10 μg
